The Rad52 protein was largely ignored in humans and other mammals when the mouse knockout revealed a largely “no-effect” phenotype. However, using synthetic lethal approaches to investigate context-dependent function, new studies have shown that Rad52 plays a key survival role in cells lacking the function of the breast cancer type 1 susceptibility protein (BRCA1)–BRCA2 pathway of homologous recombination. Biochemical studies also showed significant differences between yeast and human Rad52 (hRad52), in which yeast Rad52 can promote strand invasion of replication protein A (RPA)–coated single-stranded DNA (ssDNA) in the presence of Rad51 but hRad52 cannot. This results in the paradox of how is hRad52 providing Rad51 function: presumably there is something missing in the biochemical assays that exists in vivo, but the nature of this missing factor is currently unknown. Recent studies have suggested that Rad52 provides back-up Rad51 function for all members of the BRCA1–BRCA2 pathway, suggesting that Rad52 may be a target for therapy in BRCA pathway–deficient cancers. Screening for ways to inhibit Rad52 would potentially provide a complementary strategy for targeting BRCA-deficient cancers in addition to poly (ADP-ribose) polymerase (PARP) inhibitors. Clin Cancer Res; 18(23); 6400–6. ©2012 AACR.
Eukaryotic cells are exposed to both endogenous and exogenous insults to their genome. To foster genomic maintenance and protection, an elaborate DNA damage response (DDR) and DNA repair network evolved to encompass multiple repair pathways, each specializing in specific types of DNA lesions. Various sensor, mediator, and effector proteins are required to initiate and complete repair of damaged DNA. Deficiencies in essential components of the DDR or DNA repair pathways result in cell death or accumulation of mutations that can progress to cancer or other disease. For example, ataxia–telangiectasia, ataxia–telangiectasia–like disorder (AT-LD), Njimegen breakage syndrome (NBS), and xeroderma pigmentosum are caused by mutations of ATM (1), Mre11 (2), NBS1, and XPA, respectively. In addition, mutations in the tumor suppressor genes BRCA1 and BRCA2 greatly increase susceptibility to breast, ovarian, and other cancers (3).
One of the most threatening forms of DNA damage is the DNA double-strand break (DSB), as both strands of the DNA duplex are impaired simultaneously. The major repair pathways that cope with DSBs are nonhomologous end-joining (NHEJ) and homologous recombination. In many organisms, Rad52 is a key protein involved in the homologous recombination pathway. This review will focus on Rad52, its role in homologous recombination, and the translational opportunities available through understanding this protein and its function.
Homologous recombination pathways
Homologous recombination is the exchange of genetic information between allelic sequences and has an essential role in both meiosis and mitosis. In meiosis, homologous recombination allows for exchange of genetic material between paternal and maternal alleles within the gamete, and also coordinates proper segregation of homologous chromosome pairs during the first meiotic division.
In the somatic cell, homologous recombination maintains genomic integrity by promoting accurate repair of DSBs, damaged replication forks, and DNA interstrand cross-links. Homologous recombination repair requires a second, homologous DNA sequence to function as a donor template. In brief, the steps of DSB repair (DSBR) by homologous recombination are as follows: (i) recognition of a DSB, (ii) processing of the DSB by nucleases to generate 3′ single-stranded DNA (ssDNA) tails, (iii) formation of a Rad51 recombinase filament on ssDNA ends, (iv) strand invasion into the homologous sequence with formation of the D-loop intermediate, (v) DNA polymerase extension from the 3′ end of the invading strand, (vi) capture of the second end of the DSB by strand annealing after extension of the D-loop, (vii) formation of 2 Holliday junctions, and (viii) dissolution or resolution of the Holliday junctions to form cross-over or non–cross-over products (Fig. 1, left). Of note, the Rad51 recombinase is the essential enzyme that mediates strand invasion of a DNA duplex resulting in an exchange of DNA strands during homologous recombination.
The synthesis-dependent strand-annealing (SDSA) pathway of homologous recombination differs from the DSBR pathway by diverging following step (v) and is not dependent on the second Holliday junction formation. Rather, SDSA relies upon displacement of the invading strand and annealing it with the second resected DSB end, ultimately producing a non–cross-over product (Fig. 1, left).
When a DSB is flanked closely by sequence repeats, repair of the DSB may occur through a process called single-strand annealing (SSA). In SSA the DSB ends are resected, but rather than identifying a homologous DNA template for strand invasion, the resected strands anneal to one another using the repeat sequences for annealing. The result is a deletion of the sequence between the direct repeats (Fig. 1, right). Because SSA is independent of strand invasion, the components involved in this process, such as Rad51 filament formation, and the downstream events, including Holliday junction resolution, are not required (4).
Single-ended DSBs can occur at telomeres or at broken replication forks. These can be repaired by homologous recombination through a single-ended invasion process known as break-induced replication (BIR; ref. 5). Most BIR events are dependent on Rad51 and other homologous recombination factors used in DSBR and SDSA. This process can also occur without Rad51 protein although the Rad51-independent process is thought to be only a minor component of this reaction.
Saccharomyces cerevisiae Rad52 protein and its function in mediating recombination
The S. cerevisiae Rad52 protein (ScRad52) was identified in a genetic screen for mutants that are sensitive to ionizing radiation (8) and is the most studied recombination mediator. Indeed, many other homologous recombination genes are labeled under the heading of RAD52 epistasis group, which includes RAD50, RAD51, RAD54, RAD55, RAD57, RAD59, MRE11, and XRS2. Of all members of the RAD52 epistasis group, the absence of RAD52 confers the most severe defects due to its involvement in all known pathways of homologous recombination, both RAD51-dependent (DSBR, SDSA) and the RAD51-independent pathway of SSA (6).
Rad52 forms an oligomeric ring, and the oligomerization is mediated by the N-terminal portion of the protein (9). This N-terminal portion specifically binds ssDNA (10). ScRad52 mediates Rad51 strand invasion by physically associating with the Rad51 protein (11) and allowing for highly efficient reversal of replication protein A (RPA)–imposed inhibition of the ssDNA-dependent ATPase and recombinase activity of Rad51 (12–14).
Rad52 also directly associates with RPA (15), a heterotrimeric ssDNA-binding protein that coats the resected ends of the DSB (Fig. 1). Both the largest (RPA70) and intermediate (RPA32) subunits show direct binding with ScRad52 (16, 17). The specific interaction of RPA and ScRad52 appears important for the recombination mediator function of ScRad52. This specificity is demonstrated when RPA is substituted with the Escherichia coli single-stranded DNA-binding protein (SSB), ScRad52 is not able to overcome SSB inhibition and subsequently fails to promote Rad51-mediated homology search and strand exchange (13).
Additional functions of S. cerevisiae Rad52
ScRad52 is required for the Rad51-independent SSA and BIR reactions (4, 5). In concordance with its role in SSA, ScRad52 is able to anneal DNA strands that are either bare or coated with RPA (16, 18). There is some evidence to suggest that Rad52-mediated annealing of RPA-coated ssDNA strands is important for second ssDNA end capture in the DSBR pathway of homologous recombination (19).
Human recombination mediators: Rad52 and BRCA2
Human Rad52 (hRad52) is similar to ScRad52 structurally and biochemically. hRad52 exists in an oligomeric form, binds ssDNA, promotes ssDNA annealing, and under certain specialized conditions, simulates Rad51-mediated homologous DNA pairing (20). Like ScRad52, hRad52 has conserved the ability to directly interact with RPA (17).
Subsequent studies have examined the N-terminal portion of hRad52 to determine in detail its interaction with ssDNA. Investigation by X-ray crystallography revealed an undecameric (11-subunit) ring structure with a deep groove on the surface that is lined by a vast number of positively charged basic and aromatic residues (21, 22). These hRad52 residues have been shown to be important for ssDNA binding by mutational analysis (22, 23), and deletions of equivalent residues in ScRad52 show deficiencies in DNA repair and homologous recombination (24).
More recently, a second DNA binding domain has been discovered in hRad52, which seems to bind double-stranded DNA (dsDNA; ref. 25). Mutations of these amino acid residues are defective in promoting Rad51-mediated D-loop formation in ScRad52 (26). Further study of this second DNA-binding domain is necessary to understand how it contributes to the known functions of Rad52.
Interestingly, although hRad52 did not show recombination mediator activity in reconstituted biochemical assays (27), it seems to mediate Rad51 function in human cancer cells deficient in BRCA1, PALB2 (28), or BRCA2 (29). We postulate that hRad52 may perform its mediator function in combination with partner proteins. It has been suggested that the Rad51 paralogs Rad51B/C/D-XRCC2 may fulfill this role. However, the Rad51 paralogs seem to function primarily in the BRCA2 pathway and operate independently of hRad52 in mediating the Rad51 recombinase (30). There remain other Rad51 paralogs that may be candidate cofactors, including homolog of yeast Shu2 (hSWS1) and SWSAP1 (31). Alternatively, hRad52 recombination-mediator activity may be dependent on specific posttranslational modifications (e.g., phosphorylation, SUMOylation, etc.) that have yet to be examined biochemically.
Besides its role in Rad51 mediation, it has recently been suggested that BRCA2 participates in the stabilization of RAD51 filaments from degradation by MRE11 through interaction of BRCA2′s conserved C-terminal domain with Rad51 (32). It is unknown whether Rad52 has any role to play in this proposed mechanism of replication fork protection.
Species spectrum of Rad52 and BRCA2
BRCA2 and its homologs seem to have appropriated subsets of Rad52 function, especially in mediating recombination by Rad51, and are present in a variety of multicellular organisms (see Table 1; refs. 33–40).
A speculative assumption is that BRCA2 has evolved for the greater level of insults to the genome in multicellular organisms in comparison with unicellular organisms. Seen from another perspective, increased—but regulated—mutagenesis is evolutionarily preferential in unicellular life; however, in multicellular organisms more stringent control of DNA repair, especially in stem cells, via BRCA2 is essential for vitality. Ustilago maydis exists as a unique unicellular exception to possessing a BRCA2 homolog, possibly, to enable it to tolerate the greater levels of exogenous DNA damage (e.g., high UV exposure, etc.) it encounters in its native environment budding on crops of corn or in support of its multicellular filamentous form.
Rad52 and its synthetically lethal interactions across various species
The dual role of ScRad52 in both mediating Rad51 function and performing the annealing step in second end capture and SDSA explains why ScRad52 mutants display more severe phenotypes than defects in Rad51 protein. Unexpectedly, in organisms containing a BRCA2 homolog, including U. maydis, chicken, and mice, inactivation of Rad52 causes minimal or no homologous recombination and DNA repair defects (40–42). However, in human cancer cell lines deficient in BRCA1, PALB2 (28), or BRCA2 (29), RAD52 depletion increases damage-induced chromosomal abnormalities, decreases clonogenic survival, and further reduces the rates or frequency of homologous recombination (28, 29). Thus, RAD52 seems to exist in a relationship with BRCA1, PALB2, or BRCA2, known as synthetic lethality, in which simultaneous inactivation of 2 genes leads to cell death, whereas inactivation of only one of these genes does not affect viability. This observation is in accordance with other RAD52 synthetically lethal phenotypes seen in chicken DT40 cells, in which inactivation of rad52 is lethal with a defect in XRCC3, a Rad51 paralog (43), and in U. maydis, in which a Rad51 paralog mutant, rec2, shows synthetic lethality with loss of rad52 (40).
Interestingly, in DT40 cells, rad52 deletion in a BRCA2 mutant background did not enhance cytotoxicity; instead epistasis was observed between BRCA2 and Rad52, as well as other homologous recombination proteins (44). Also, in U. maydis, Brh2 mutants in combination with Rad52 defects show a more subtle synthetically lethal phenotype, which the study's authors interpret as a compensatory interaction (40). These observed divergences from human and other studied organisms will require further investigation to delineate the hierarchy and functional nuances of these various homologous recombination proteins across the evolutionary spectrum.
Dependency of BRCA1-PALB2-BRCA2–deficient human tumor cells on Rad52-Rad51–mediated homologous recombination
BRCA1, PALB2, and BRCA2 seem to be linked in a sequential manner. BRCA2 recruitment to foci requires interaction with PALB2, and abolishment of the physical interface between BRCA1 and PALB2 impairs BRCA2 function and subsequently Rad51-mediated homologous recombination (45–47). Evidence suggests Rad52 provides an alternative mediator pathway to the BRCA1-PALB2-BRCA2 pathway and allows tumor cells to proliferate in the absence of the BRCA pathway (Fig. 1). The loss of Rad52 in a BRCA1, PALB2 (28), or BRCA2 (29) mutant leads to cell death.
These observations set the potential foundation for any BRCA1-PALB2-BRCA2 pathway–deficient tumor to be therapeutically targeted by Rad52 inactivation. This approach for targeting BRCA pathway–deficient cancers is distinct from other strategies that take advantage of synthetic lethality in BRCA mutant tumors, namely PARP inhibition. These translational approaches and discoveries that exploit homologous recombination–defective cancers will be highlighted in the subsequent section.
Exploiting synthetic lethal interactions in homologous recombination deficient tumors
Synthetic lethality can be exploited therapeutically by identifying cells with a cancer-related mutation or loss of a single gene that can then be evaluated for a second gene or protein target that would render the cancer cells nonviable. Because the loss of the second gene alone is not lethal to normal cells, tumor-specific kill can be achieved. This approach has been employed to great promise and effect in homologous recombination–deficient BRCA1- and BRCA2-mutant cancers, and is being expanded to many cancers with tumor-specific alterations that are potentially exploitable, such as oncogene addiction.
PARP inhibition in BRCA1-BRCA2–deficient tumors.
PARP inhibitors (PARPi) are synthetically lethal with BRCA-defective tumor cells (48, 49). The presumed mechanistic model for this lethal interaction is the inhibition of PARP that prevents repair of ssDNA breaks, which accumulate and are then converted into DSBs during replication. The DSBR homologous recombination pathway is impaired in BRCA1-BRCA2 mutant tumors, leading to a lethal amount of DSBs after PARP inhibition. However, new evidence has suggested other models that build upon or modify this assumed mechanism. One model proposes that PARPi may cause PARP-1 to be trapped onto DNA repair intermediates that then stall replication forks, or another suggests that PARP is directly involved in catalyzing the restart of stalled replication forks. There are excellent reviews for further discussion of this topic (50, 51).
Regardless of the mechanism, the use of PARPi to target BRCA-mutant cancers has moved beyond the laboratory and into clinical trials with promising results (52–55). However, even in these studies, some BRCA-mutant carriers respond poorly (52), and resistance to PARPi therapy via BRCA2-reversion mutations has been documented (56). In addition, expression of the multidrug resistance transporter also results in resistance to PARPi. These observations highlight the need to identify biomarkers that will predict patient response to PARP inhibition and the development of additional strategies for exploiting BRCA pathway deficiency.
Targeting Rad52 in BRCA1-BRCA2–deficient tumors.
The rationale for targeting Rad52 in BRCA-deficient tumors was established by the preclinical evidence covered in the preceding sections. In addressing the inactivation of Rad52 in the clinical setting, a variety of approaches can be examined. One approach would be to target Rad52 directly. Currently, there are no known enzymatic or kinase functions of Rad52, which preclude the more well-studied pharmacologic approaches. However, as advances are made by molecular pharmacologists and medicinal chemists, creating or identifying a compound that disrupts the oligomer ring structure or binds in the vicinity of the DNA-binding groove of Rad52 to prevent access by the DNA substrate may be potential molecular mechanisms. These approaches will require high-throughput screening with libraries of compounds as a top-down approach coupled with other investigations from a bottom-up mechanistically driven strategy.
Targeting posttranslational modifications of Rad52 that are essential for function is another promising avenue of approach. Rad52 is phosphorylated by the c-Abl kinase, which affects its ability to form subnuclear foci (57) and enhances its annealing functions (58). Disrupting the c-Abl kinase through genetic and pharmacological approaches in preliminary studies seemed to disrupt Rad52 function (59). Another posttranslational modification that contributes to Rad52 function is SUMOylation, which may be another potential target for impeding Rad52 function (60–64). The interaction of Rad52 with RPA may also be a potentially targetable site, but developing drugs to inhibit protein–protein interactions has always been a challenging problem. Whether these strategies will result in clinically applicable therapeutics remains to be seen.
Identification of BRCA pathway–deficient cancers susceptible to synthetically lethal therapeutic approaches
Even with the mechanistic understanding of these realized and potential therapeutic approaches, proper identification of tumors susceptible to these interventions is equally important. A potent intervention applied to an improper scenario/disease-state will result in disappointingly ineffectual or even harmful outcomes.
Indeed, one of the primary target proteins of PARPi, PARP-1, displays a spectrum of protein expression levels even within genetically similar tumor types. In this regard, not all BRCA1-associated breast cancers are created equal, with up to 18% of these tumors expressing none or low levels of nuclear PARP-1 protein (65). This is suggestive that investigating target protein expression levels in tumors may be one approach to predict patient response to PARPi therapy.
The homologous recombination proficiency of a tumor can be measured by observing subnuclear focus formation of homologous recombination proteins induced by ex vivo irradiation, including BRCA1 and Rad51 among others (66, 67), and these homologous recombination foci formation assays correlate with the PARPi sensitivity of these tumors (68). This functionally driven approach allows for more precise patient identification, in addition to expanding the potential pool of targetable tumors, through establishing a predictive biomarker for homologous recombination–deficient tumors that are not identified by the traditional genetic test for the BRCA1 or BRCA2 mutation.
We are entering an exciting era of precision-targeted and personalized cancer therapy. With the greater understanding and continual investigation of the complex genetic interactions of oncogenesis and tumor proliferation, rational design of and molecular target identification by various therapeutic methods can be accomplished. Success will also depend on the development of biomarkers of DNA repair function to identify appropriate patients for targeted therapy. Continual and further elucidation of the mechanisms of DNA repair will be paramount to devising therapeutics, identifying appropriate patients, evaluating responsiveness, and preventing resistance to targeted therapeutic strategies.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Conception and design: B.H. Lok, S.N. Powell
Writing, review, and/or revision of the manuscript: B.H. Lok, S.N. Powell
Work on homologous recombination in S.N. Powell's laboratory is supported by grants from the National Cancer Institute (CA58985 and CA86140) and Susan G. Komen for the Cure (KG081528). B.H. Lok was supported in part by a medical research training fellowship from the Howard Hughes Medical Institute (57007004) and a medical student research grant from the Radiological Society of North America (RMS1009).
We apologize to those investigators whose work could not be cited owing to space limitations.
- Received August 14, 2012.
- Revision received September 18, 2012.
- Accepted September 19, 2012.
- ©2012 American Association for Cancer Research.